Citi analyst Liav Abraham raised her price target for Endo International to $19 saying the Q2 results validated her Buy thesis, which is predicated on “solid execution” across the core businesses and the opportunity inherent in the company’s CCH cellulite opportunity. She sees more upside in shares of Endo and keeps a Buy rating on the shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.